A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis

Neurology

Volumn 51, Issue 1, 1998, Pages 239-245

  Goodkin, D E ^b   Kinkel, R P ^a   Weinstock Guttman, B ^a   VanderBrug Medendorp, S ^a   Secic, M ^a   Gogol, D ^a   Perryman, J E ^a   Uccelli, M M ^a   Neilley, L ^b  

^a Meilen Ctr Multiple Sclerosis T   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE;

ACNE; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISABILITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DYSPEPSIA; HUMAN; INSOMNIA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0031817597     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.1.239     Document Type: Article

References (14)

1. Oksenberg JR, Hauser SL. Pathogenesis of multiple sclerosis: relationship to therapeutic strategies. In: Goodkin DE, Rudick RA, eds. Treatment of multiple sclerosis: advances in trial design, results and future perspectives. London: Springer-Verlag, 1996:17-46.
2. Lublin FD, Reingold SC, for the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911.
3. Andersson PB, Goodkin DE. Glucocorticosteroid therapy for multiple sclerosis: a critical review. J Neurol Sci 1998 (in press).
4. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability scale (EDSS). Neurology 1983;33: 1444-1452.
5. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized three-arm study of high dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983;308:173-180.
6. Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil 1988;69:850-854.
7. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bull 1945;1:80-83.
8. Fisher RA. On the interpretation of the chi-square from contin gency tables and the calculation of P. J R Stat Soc 1922;85: 87-94.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1937;32:675-701.
10. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc Series A 1972;135:185-198.
11. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34:187-220.
12. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology 1994;44:16-20.
13. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate is effective in reducing the rate of progression of neurological impairment in patients with chronic progressive multiple sclerosis. Ann Neurol 1995; 37:30-40.
14. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994;344:9-13.